公开(公告)号：US20250161322A1

公开(公告)日：2025-05-22

申请号：US18817828

申请日：2024-08-28

Applicant: Genentech, Inc.

Inventor： Kui Lin

IPC: A61K31/566 ,  A61K9/00 ,  A61K31/138 ,  A61K31/517 ,  A61K31/519

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

公开(公告)号：US12083129B2

公开(公告)日：2024-09-10

申请号：US18101377

申请日：2023-01-25

Applicant: Genentech, Inc.

Inventor： Kui Lin

IPC: A61K31/566 ,  A61K31/138 ,  A61K31/517 ,  A61K31/519 ,  A61K9/00

CPC classification number: A61K31/566 ,  A61K31/517 ,  A61K31/519 ,  A61K9/0019 ,  A61K31/138

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

公开(公告)号：US20170065588A1

公开(公告)日：2017-03-09

申请号：US15237412

申请日：2016-08-15

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Elizabeth Punnoose ,  Somasekar Seshagiri

IPC: A61K31/517 ,  C12Q1/68 ,  A61K31/58 ,  G01N33/574

CPC classification number: A61K31/517 ,  A61K31/58 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5748

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.

Abstract translation: 本文提供了用于预测对癌症治疗的敏感性的生物标志物和生物标志物的组合。

公开(公告)号：US20160228440A1

公开(公告)日：2016-08-11

申请号：US15017315

申请日：2016-02-05

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Michelle Nannini ,  Elizabeth Punnoose ,  Deepak Sampath ,  Jeffrey Wallin ,  Premal Patel

IPC: A61K31/517 ,  A61K31/4166

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Abstract translation: 本发明提供组合，其包含a）式I化合物或其药学上可接受的盐，其中R 1，R 2，R 5，R 10和A具有说明书中定义的任何值; 和b）选自5-FU，铂药剂，甲酰四氢叶酸，伊立替康，多西他赛，多柔比星，吉西他滨，SN-38，卡培他滨，替莫唑胺，紫杉醇，贝伐珠单抗，依托单抗，他莫昔芬，雷帕霉素和拉帕替尼的一种或多种药剂。 这些组合对于治疗过度增殖性疾病如癌症特别有用。

公开(公告)号：US20180327860A1

公开(公告)日：2018-11-15

申请号：US15974533

申请日：2018-05-08

Applicant: GENENTECH, INC.

Inventor： Kui Lin

IPC: C12Q1/6886 ,  A61K31/5377 ,  A61K31/436 ,  A61K31/517

CPC classification number: C12Q1/6886 ,  A61K31/436 ,  A61K31/517 ,  A61K31/5377 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.

公开(公告)号：US11576919B2

公开(公告)日：2023-02-14

申请号：US16989528

申请日：2020-08-10

Applicant: Genentech, Inc.

Inventor： Kui Lin

IPC: A61K31/566 ,  A61K31/517 ,  A61K31/519 ,  A61K31/138 ,  A61K9/00

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

公开(公告)号：US20180360835A1

公开(公告)日：2018-12-20

申请号：US16122713

申请日：2018-09-05

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Elizabeth Punnoose ,  Somasekar Seshagiri

IPC: A61K31/517 ,  A61K31/58 ,  G01N33/574 ,  C12Q1/6886

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.

公开(公告)号：US09994913B2

公开(公告)日：2018-06-12

申请号：US14832594

申请日：2015-08-21

Applicant: Genentech, Inc.

Inventor： Kui Lin

IPC: A61K31/517 ,  C12Q1/68 ,  A61K31/436 ,  A61K31/5377

CPC classification number: C12Q1/6886 ,  A61K31/436 ,  A61K31/517 ,  A61K31/5377 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.

公开(公告)号：US20170157124A1

公开(公告)日：2017-06-08

申请号：US15438277

申请日：2017-02-21

Applicant: Genentech, Inc.

Inventor： Kui Lin ,  Michelle Nannini ,  Elizabeth Punnoose ,  Deepak Sampath ,  Jeffrey Wallin ,  Premal Patel

IPC: A61K31/517 ,  A61K31/337

CPC classification number: A61K31/517 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4166 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/58 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07D239/70 ,  C07D403/12 ,  C07K16/40 ,  A61K2300/00

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

公开(公告)号：US20230330106A1

公开(公告)日：2023-10-19

申请号：US18101377

申请日：2023-01-25

Applicant: Genentech, Inc.

Inventor： Kui Lin

IPC: A61K31/566 ,  A61K31/519 ,  A61K31/517

CPC classification number: A61K31/566 ,  A61K31/517 ,  A61K31/519 ,  A61K9/0019

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.